WALTHAM, Mass.--(BUSINESS WIRE)--Oscient Pharmaceuticals Corporation (Nasdaq: OSCI) will participate in the Sixth Annual JMP Securities Research Conference on Tuesday, May 22, 2007 in San Francisco. The Company’s President and CEO, Steven Rauscher, will provide an overview of the Company including details on the recent approval of FACTIVE® (gemifloxacin mesylate) tablets for the five-day treatment of community-acquired pneumonia and the market performance of ANTARA® (fenofibrate) capsules and FACTIVE in the U.S.
